Drug intelligence / Profile preview

YD01-2022

Development stage: Phase 2
Lead developer: Shanghai Jiao Tong University School of Medicine
Modality: Cell Therapies
Administration: Parenteral

Overview

YD01-2022 is an autologous cell therapy consisting of expanded pancreatic islet cells, currently under investigation for the treatment of diabetes mellitus following total pancreatectomy. The therapy involves the isolation of islet cells from a patient's own pancreas, followed by an in vitro expansion process to increase the functional cell mass before re-transplantation. This approach is designed to restore endogenous insulin production and improve glycemic control in patients who would otherwise be completely insulin-dependent and at risk for severe hypoglycemic episodes. The primary clinical focus is on patients undergoing total pancreatectomy for conditions such as chronic pancreatitis or pancreatic tumors.

Other names: Autologous expanded pancreatic islet cells

Beyond the preview

Go deeper on YD01-2022.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on YD01-2022.

Explore the full profile